Plasmodium vivax usually causes an acute self-limiting febrile illness with fever spikes on every third day and no complications or death.
We obtained health surveillance epidemiologic data on malaria among French military personnel deployed to French Guiana during 1998–2008. Incidence of Plasmodium vivax malaria increased and that of P. falciparum remained stable.
Plasmodium vivax malaria is a debilitating, sometimes life-threatening, and economically repressive disease of many tropical and temperate countries outside Africa, and yet it is perceived as relatively benign.
Gestational malaria is a multi-factorial syndrome leading to poor outcomes for both the mother and foetus.
Of the three RDTs, the CSPfPan test was the most consistent and reliable, rendering it appropriate for this P. vivax predominant region.
In this study we demonstrated that P. vivax infections were found both in humans and mosquitoes, which means that active transmission is occurring.
In this study, we establish a novel visualized LAMP method in a closed-tube system, and validate it for the diagnosis of malaria under simulated field conditions.
Twenty-three patients of Pv malaria were retrospectively analyzed. Thrombocytopenia was present in 22 (96%) patients with counts less than 50,000/μL in 9 patients. Severe anemia (hgb < 5 mg/dl) was present in 8 (34%) patients. Cerebral malaria was present in 3 patients.
P. vivax-associated coma is rare, occurring 23 times less frequently than that seen with falciparum malaria, and is associated with a high proportion of non-malarial causes and mixed infections using PCR.
To investigate whether Pvs230 can be a vivax malaria transmission-blocking vaccine, we performed evolutionary and population genetic analysis of the Pvs230 gene (pvs230: PVX_003905).